Table 1.
Clinicopathological Characteristics of Colorectal Carcinoma Patients and SPAG9 Expression
| Clinicopathological characteristics | SPAG9 expression⁎ |
|
|---|---|---|
| ELISA, n/N (%) | RT-PCR/IHC, n/N (%) | |
| Tumor, total | 38/54 (70) | 58/78 (74) |
| ANCT, total | 0/26 (0) | |
| Normal colon tissue, total | 0/40 (0) | |
| Tumor stages | ||
| Stage I | 1/1 (100) | 7/10 (70) |
| Stage II | 11/11 (100) | 16/16 (100) |
| Early stages (I + II) | 12/12 (100) | 23/26 (88) |
| Stage III | 20/33 (61) | 29/43 (67) |
| Stage IV | 6/9 (67) | 6/9 (67) |
| Late stages (III + IV) | 26/42 (62) | 35/52 (67) |
| Histologic grades | ||
| Well differentiated | 17/23 (74) | 28/37 (76) |
| Moderately differentiated | 17/23 (74) | 26/33 (79) |
| Mucinous | 4/8 (50) | 4/8 (50) |
| Lymph node involvement | ||
| Positive | 26/41 (63) | 30/45 (67) |
| Negative | 12/13 (92) | 28/33 (85) |
| Metastasis | ||
| Positive | 7/10 (70) | 11/14 (79) |
| Negative | 31/44 (70) | 47/64 (73) |
ANCT, adjacent noncancerous tissue; ELISA, enzyme-linked immunosorbent assay; IHC, immunohistochemistry.
⁎
The ELISA analysis detected circulating autoantibodies against SPAG9. The RT-PCR and IHC analyses detected SPAG9 mRNA expression.